Get Started

LYCA

NASD Lycia Therapeutics, Inc.
Nov 1, 2026 · 8:41 PM ET EOD Market Closed

$26.40 ↑ +0.00 (+0.00%) Trading Up from the previous close of $26.40, $1.19 below the day’s high of $27.59

YTD change
-12.00%
vs 20-day SMA
N/A
vs 200-day SMA
N/A

Price ranges

Previous day
$25.66 $27.59
open $27.17 close $26.40
-$0.77 (-2.83%)
Today
$25.66 $27.59
$26.40
Past week
$22.19 $36.49
from $30.00 now $26.40
-$3.60 (-12.00%)
Past month
$0.00 $30.00
from $30.00 now $26.40
-$3.60 (-12.00%)
This year
$22.19 $36.49
from $30.00 now $26.40
-$3.60 (-12.00%)

Price & Performance

-3.60 (-12.00%) / 6M

$24.65$26.57$28.48$30.40Oct 23Oct 27Oct 30

Signals & Sentiment

Momentum, market sentiment, and recent alerts

N/A
  • The stock is 27.7% away from all-time highs of $36.49
  • LYCA is down 12% since the beginning of the year
  • LYCA is down 12% over the past 12 months
  • LYCA is down 12% over the past 1 month

LYCA reads n/a: the 12-month move is -12.0%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable N/A
EPS N/A
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $1.7B

Balance sheet & scale

IncomeN/A
Revenue$6.7M
Cash$79.1M
Debt$205.1K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Market cap $1.5B

Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.